OncoVista said it entered a stock purchase agreement with an unnamed buyer on Oct. 28 and sold all of its shares, representing approximately 78 percent of the total issued and outstanding shares

Adamis Pharmaceuticals Corp., of San Diego, signed a $10 million common stock purchase agreement with Eses Holdings Ltd., a company located in the United Arab Emirates, allowing Eses to acquire 40 million shares of Adamis' common stock at 25 cents per share

Lazard Capital Markets LLC served as the lead placement agent, and Roth Capital Partners LLC served as the co-placement agent for the offering (10/6) Cytomedix Inc. (AMEX:GTF) Registered direct offering 3.7S and W for 1 .8S $13 Cytomedix secured a $13M financing through a registered direct offering of shares and warrants, plus $10M and $1.5M equity purchase agreements (10/11) DARA BioSciences Inc. (DARA) Registered direct offering 0.613U $1 .4 DARA raised $1.4M in an

Marina Biotech Inc., of Bothell, Wash., entered a securities purchase agreement with investors to sell up to $8.7 million in common stock

secured $13 million through a registered direct offering and equity purchase agreements

Oxygen Biotherapeutics Inc., of Durham, N.C., entered a note purchase agreement with JP SPC 1 Vatea Segregated Portfolio in which the company agreed to issue and sell to the Vatea Fund an aggregate of $5 million of senior unsecured promissory notes in a series of closings between Oct. 31 and Dec. 31...Vatea, the company's largest shareholder, is a party to a securities purchase agreement with the company, dated June 8, 2009, and subsequently amended

Cytomedix Inc., of Gaithersburg, Md., has secured about $13 million in current and future funding through a registered direct offering and commitments under two separate equity purchase agreements...The securities purchase agreement with certain existing shareholders and a new institutional investor is for the sale of 3,727,677 shares of its common stock in the offering priced at 40 cents per share for non-affiliates and 53 cents for affiliates

Dynavax will receive another $28M over the next 25 months as part of the deal (9/22) EntreMed Inc. (ENMD) Securities purchase agreement N/A $5.1 EntreMed raised $5.1M through a group of investors (9/9) Genesis Biopharma Inc. (OTC BB:GNBP) Private placement of common stock and warrants 0.93S and W for 0.47S $0.7 Genesis Biopharma raised $700,000 through the private offering (9/24) Lorus Therapeutics Inc. (Canada; TSX:LOR) Rights offering 5S $5.5 Lorus raised $5.5M by

Curaxis Pharmaceutical Corp., of Durham, N.C., and Southridge LLC, of Ridgefield, Conn., jointly announced a $25 million equity purchase agreement with institutional investor Southridge Partners II

The initial investment was part of a $30 million at-the-market stock purchase agreement in which Aspire Capital has committed to purchase up to an additional $28 million of Dynavax common stock over the next 25 months

Aradigm Corp., of Hayward, Calif., closed its previously announced stock purchase agreement with Bagsvaerd, Denmark-based Novo Nordisk A/S. Aradigm sold 26 million shares of common stock to Novo in a private placement, eliminating a $9.1 million loan

EntreMed Inc., of Rockville, Md., entered a securities purchase agreement with a group of investors for gross proceeds of about $5.1 million

it also entered a purchase agreement with MHR Fund Management LLC to sell 3.5M shares and warrants for 2.6M shares (8/30) Helix BioPharma Corp. (Canada; TSX:HBP) Private placement of units 4.53U $11 Helix closed a private placement of 4.53M units at $2.43 each

purchase agreement with Alternecare, which combines rapid home diagnostics with therapeutic nutraceutical-based solutions Amaxa AG* (Germany) Lonza Group (Switzerland; LSE:LNA) 7/3 7/3 ND Lonza acquired Amaxa, which supplies transfection technologies to the cell discovery market Apollo Cytokine Research* (Australia) Symansis* 6/25 6/25 A$0.5 ($0.48) Symansis acquired Apollo for $479,602 Applied Biosystems Group (a subsidiary of Applera Corp.; NYSE:ABI) Invitrogen Corp. (IVGN) 6/12 11/24 $6

Emisphere also entered a separate securities purchase agreement with MHR Fund Management LLC, under which it will sell about 3.5 million shares and warrants for 2.6 million shares

Company* (Country; Symbol) Company* (Country; Symbol Type/Product Area Terms/Details (Date) FIRST QUARTER Accentia Bio- Revimmune Accentia acquired ex- Accentia is preparing an investigational Pharmaceuticals LLC* clusive worldwide rights new drug application for severe refractory Inc. (ABPI) to autoimmune disease multiple sclerosis and is proposing a drug Revimmune Phase III program (2/28) Advanced Cell Infigen Inc.* Agreement for intellectual A total of 26 issued patents and a

Raptor Pharmaceutical Corp., of Novato, Calif., is selling 4,897,614 units at $3.075 per unit for gross proceeds of about $15 million under a securities purchase agreement in connection with a private placement

Aradigm Corp., of Hayward, Calif., said that it has entered into a stock purchase agreement providing for the issuance of 26 million shares of the company's common stock to Novo Nordisk A/S, of Bagsvaerd, Denmark, in a private placement in exchange for eliminating a $9.1 million loan, representing an effective price per share of $0.3505

Aradigm Corp., of Hayward, Calif., said that it has entered into a stock purchase agreement providing for the issuance of 26 million shares of the company's common stock to Novo Nordisk A/S, of Bagsvaerd, Denmark, in a private placement in exchange for eliminating a $9.1 million loan, representing an effective price per share of $0.3505